Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Passaro

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyA Passaro, J Wang, Y Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyA Passaro, J Wang, Y Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Pageof 7